SILVAZINE CREAM

Product Information

Registration Status: Inactive

THIS PRODUCT HAS BEEN DEREGISTERED!

SILVAZINE CREAM is approved to be sold in Singapore with effective from 1990-02-22. It is marketed by SMITH & NEPHEW PTE LIMITED, with the registration number of SIN04015P.

This product contains Chlorhexidine Digluconate 2mg/g, and Silver Sulphadiazine 10mg/g in the form of CREAM. It is approved for TOPICAL use.

This product is manufactured by SIGMA PHARMACEUTICALS PTY LTD in AUSTRALIA.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Chlorhexidine Digluconate
Silver Sulphadiazine


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


Description

Silver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.

Indication

Indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.

Mechanism of Action

Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine. Silver sulfadiazine acts only on the cell membrane and cell wall to produce its bactericidal effect. A specific mechanism of action has not been determined, but silver sulfadiazine's effectiveness may possibly be from a synergistic interaction, or the action of each component. Silver is a biocide, which binds to a broad range of targets. Silver ions bind to nucleophilic amino acids, as well as sulfhydryl, amino, imidazole, phosphate, and carboxyl groups in proteins, causing protein denaturation and enzyme inhibition. Silver binds to surface membranes and proteins, causing proton leaks in the membrane, leading to cell death. Sulfadiazine is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.

Pharmacokinetics

Absorption
Very limited penetration through the skin. Only when applied to very large area burns is absorption into the body generally an issue.
Distribution
Metabolism
Elimination

Toxicity

Acute oral toxicity (LD50) in rat is 10001 mg/kg.

Active Ingredient/Synonyms

Silver sulfadiazinate | Silver sulfadiazine | Silver sulphadiazine | Sulfadiazine silver | Sulfadiazine silver salt | Silver sulfadiazine |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank